Chronic rhinosinusitis with nasal polyps (CRSwNP)
Conditions
Interventions
Control group (Group A): Treated with the traditional FESS procedure:fess surgical operation
Experimental group (Group B): Surgical treatment was performed using the Partial Reboot technique.:Partial Reboot surgical operation
Sponsors
The Third Affiliated Hospital Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients aged >=18 years meeting the diagnostic criteria for CRSwNP (persistent symptoms >=12 weeks, with endoscopic or CT-confirmed bilateral polyps); 2.Disease duration >=1 year with poorly controlled symptoms after >=3 months of standardized pharmacotherapy, requiring surgical intervention; (Definition of standardized pharmacotherapy: Basal medication includes intranasal corticosteroids (INCS) + isotonic saline irrigation, which may be combined with short-course systemic corticosteroids and/or antibiotics); 3.Presence of at least one clinical feature: bronchial asthma, allergic rhinitis, or olfactory dysfunction; 4.Preoperative evidence of type II inflammation meets any of the following criteria: peripheral blood eosinophil count >=0.3×10?/L or serum total IgE >=100 IU/mL; 5.The subjects voluntarily participated in the study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.radiation-induced sinusitis, primary ciliary dyskinesia, cystic fibrosis, EGPA, IgG4-related disorders, or iatrogenic sinusitis; 2.Patients who have not received standardized pharmacotherapy; those who have used systemic glucocorticoids within the past 4 weeks or biologics within the past 6 months; 3.History of nasal or sinus surgery; 4.Patients with severe cardiovascular or cerebrovascular diseases, hematologic disorders, malignancies, or those who cannot tolerate general anesthesia due to systemic conditions; 5.Pregnant or breastfeeding women; 6.Acute upper respiratory tract infection within the past 4 weeks; 7.Those with poor adherence or who are expected to be unable to complete follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Type II Inflammatory Biomarkers in Nasal Secretions; | — |
Secondary
| Measure | Time frame |
|---|---|
| snot-22 score;Histopathological grading of inflammation;Meltzer score;Lund-Kennedy score;Electron microscopy examination;Peripheral blood test indicators;Olfactory score;VAS grade;Lund-Mackay score; | — |
Countries
China
Contacts
Public ContactShuo Wu
The Third Affiliated Hospital Sun Yat-sen University
Outcome results
None listed